Hormonal
Once-weekly 2.4 mg semaglutide produces significant weight loss and cardiometabolic improvements in adults with obesity, regardless of whether the treatment is combined with standard or very intensive lifestyle interventions.
Take 2.4 mg of semaglutide once weekly, starting with a low dose (0.25 mg) and increasing every 4 weeks to minimize side effects. While you should still eat healthy and exercise, do not expect lifestyle changes to significantly boost weight loss beyond what the medication provides. The drug itself is the primary driver of weight loss.
In all the STEP studies, despite the varying intestines of the behavioral programs, weight loss was very similar. For the first time, there may be a suggestion that these behavioral programs might not increase weight reduction beyond the effect of semaglutide.
Why this rating
Based on multiple phase-III, randomized, double-blind, placebo-controlled trials (STEP 1-8).
Source
The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
Khaled Alabduljabbar et al. · Nutrients · 2022
DOI 10.3390/nu14112217
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →